Related Experiment Videos
An announced suicide with ecstasy
Kathrin Libiseller1, Marion Pavlic, Petra Grubwieser
1Institute of Legal Medicine, Innsbruck Medical University, Muellerstrasse 44, 6020, Innsbruck, Austria. kathrin.libiseller@uibk.ac.at
International Journal of Legal Medicine
|September 22, 2005
Summary
This study details an announced suicide using a combination of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA). Toxicological analysis revealed high serum concentrations of these designer drugs, suggesting a deliberate overdose.
Area of Science:
- Forensic Toxicology
- Clinical Chemistry
- Pharmacology
Background:
- Designer drug use, particularly 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA), is often associated with accidental overdose.
- Suicide attempts involving designer drugs are infrequent but documented.
- This case involves an announced suicide using a combination of MDMA and MDEA.
Observation:
- Autopsy included comprehensive toxicological sampling from blood, urine, cerebrospinal fluid, bile, and gastric contents.
- High serum concentrations of MDMA (13.33 mg/l), MDEA (7.32 mg/l), and 3,4-methylenedioxyamphetamine (0.43 mg/l) were detected.
- Confiscated ecstasy tablets contained both MDMA and MDEA, matching the substances found in the deceased.
Findings:
- The toxicological profile confirmed a significant intake of MDMA and MDEA.
- The presence of both drugs in the deceased and in seized ecstasy tablets suggests a common source.
- This case represents a rare instance of announced suicide via combined MDMA and MDEA ingestion.
Implications:
- Highlights the potential lethality of combined MDMA and MDEA, even in non-accidental scenarios.
- Underscores the importance of comprehensive toxicological analysis in suspected drug-related fatalities.
- Provides data on serum concentrations achievable with combined MDMA/MDEA use in a fatal overdose context.